Daiichi Sankyo doses first patient in Phase 1 trial of DS1025 CD25-targeted ADC for advanced solid tumors

PUBT · 3d ago
Daiichi Sankyo doses first patient in Phase 1 trial of DS1025 CD25-targeted ADC for advanced solid tumors
  • Daiichi Sankyo dosed the first patient in a first-in-human phase 1 trial of DS1025 in advanced or metastatic solid tumors.
  • Study targets adults whose disease progressed on or after at least one prior line of standard therapy.
  • DS1025 is an investigational, engineered CD25-directed antibody-drug conjugate with an immuno-oncology optimized cytotoxic payload.
  • CD25 is highly expressed on regulatory T cells; no CD25-directed ADCs are approved for any cancer.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Daiichi Sankyo Co. Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 202608270700BIZWIRE_USPR_____20260827_BW025720) on August 27, 2026, and is solely responsible for the information contained therein.